arrow
J

Jason J. Luke

UPMC Hillman Cancer Center and University of Pittsburgh
H指数:63
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials

细胞因子释放症状而非综合征:呼吁在临床试验中详细报告细胞因子相关不良事件

2026-04-020
PRE
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors

I期b研究:达唑替尼加帕博利珠单抗在特定晚期实体瘤患者接受低分割放射治疗后的应用

2025-12-010
OA
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer

整合人工智能驱动的数字病理学和基因组学,以建立基于患者来源的类器官作为头颈癌药物反应的新方法学。

2025-11-090
OAAI
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

Nguyen, M.K.; Jelinek, M.; Singh, A.; Isett, B.; Myers, E.S.; Mullett, S.J.; Eisele, Y.; Beumer, J.; Parise, R.; Urban, J.; et al. 关于ivosidenib联合nivolumab治疗携带IDH1突变的晚期实体瘤的临床与转化研究。medRxiv 2025. [Google Scholar] [CrossRef]

2025-11-010
PRE
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

I期临床试验:评估ataxia telangiectasia和Rad3-related抑制剂berzosertib联合伊立替康治疗晚期实体瘤患者的疗效(ETCTN 9938)

Cancer
IF5.1
2025-10-290
PRE
Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma

Monson, K.R.; Ferguson, R.; Handzlik, J.E.; Morales, L.; Xiong, J.; Chat, V.; Dagayev, S.; Khodadadi-Jamayran, A.; Simpson, D.; Kazlow, E.; 等. 继承的线粒体遗传学作为预测黑色素瘤免疫检查点抑制疗效的指标。Nat. Med. 2025, 31, 2385–2396. [Google Scholar] [CrossRef]

2025-06-050
OAAI
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
2025-05-300
OAAI
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial

快速整合生物标志物计划在指导免疫肿瘤临床试验中的合理性与可行性:ADVISE试验

2025-05-190
OA
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial

Pembrolizumab在II期黑色素瘤中的辅助治疗: 随机,双盲,III期KEYNOTE-716试验中原发性肿瘤位置的结果

2025-02-010
PRE
A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations

一项I期、首次人体、剂量递增和扩展研究,评估口服泛RAF/MEK分子胶NST-628在携带RAS-MAPK通路异常的实体瘤受试者中的效果。

2024-09-010
PRE
Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial

mRNA-4157(V940)联合pembrolizumab或pembrolizumab单药治疗在切除的黑素瘤中复发的机制:来自mRNA-4157-P201(KEYNOTE-942)试验

2024-09-010
PRE
Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716

帕博利珠单抗(pembro)对比安慰剂作为高危Ⅱ期黑色素瘤辅助治疗:长期随访、再挑战与交叉研究(KEYNOTE-716)

2024-09-012
PRE
First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors

HST-1011(一种口服CBL-B抑制剂)在晚期实体瘤患者中的首次人体(FIH)I期数据

2024-09-010
PRE
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non - small cell lung cancer, and renal cell carcinoma
2024-08-010
OAAI